Retracted: ‚ÄòClinical trials in Alzheimer‚Äôs disease‚Ä? immunotherapy approaches
Authors: C√©line Caillaud
Julien Delrieu
Pierre Jean Ousset
Bruno Vellas
Journal: Journal of Neurochemistry (2012)
Discipline: NEUROSCIENCE & BEHAVIOR
Keywords: Alzheimer's disease; Amyloid Œ≤ peptide; Immunotherapy; Pre-clinical studies; Adverse events
Affiliations: Alzheimer‚Äôs Disease Clinical Research Centre, G√©rontop√¥le, Toulouse University Hospital, France

Abstract:  Recent advances in the understanding of Alzheimer's disease pathogenesis have led to the development of numerous compounds that might modify the disease process. Amyloid Œ≤ (AŒ≤) peptide represents an important molecular target for intervention in Alzheimer's disease. Several types of AŒ≤ peptide immunotherapy for Alzheimer's disease are under investigation, direct immunization with synthetic intact AŒ≤(42) , active immunization involving the administration of synthetic fragments of AŒ≤ peptide conjugated to a carrier protein and passive administration with monoclonal antibodies directed against AŒ≤ peptide. Pre-clinical studies showed that immunization against AŒ≤ peptide can provide protection and reversal of the pathology of Alzheimer's disease in animal models. Indeed, several adverse events have been described like meningoencephalitis with AN1792, vasogenic edema and microhemorrhages with bapineuzumab. Although immunotherapy approaches resulted in clearance of amyloid plaques in patients with Alzheimer's disease, this clearance did not show significant cognitive effect for the moment. Currently, several AŒ≤ peptide immunotherapy approaches are under investigation but also against tau pathology. 

Retracted: Yes

PubPeer comments:
 2021 retraction. https: onlinelibrary.wiley.com doi 10.1111 jnc.15435 The article by Julien Delrieu, Pierre Jean Ousset, Cu00e9line Caillaud and Bruno Vellas, entitled u201cu2018Clinical trials in Alzheimeru2019s diseaseu2019: immunotherapy approachesu201d, published in the Journal of Neurochemistry 2012, volume 120, Supplement 1, pages 186-193, published online on August 30, 2011 in Wiley Online Library has been retracted by agreement between the authors, the journal Editor-in-Chief, Andrew Lawrence, and John Wiley Sons Limited. The retraction has been agreed due to sections of text being verbatim or almost verbatim from prior publications without direct attribution to the source(s) including from the following sources: Kerchner GA, Boxer AL (2010) Bapineuzumab. Expert Opin Biol Ther 10(7): 1121- 1130. https: doi.org 10.1517 14712598.2020.493872 Coley N, Andrieu S, Delrieu J, Voisin T, Vellas B (2009) Biomarkers in Alzheimeru2019s disease: not yet surrogate endpoints. Annals of the New York Academy of Sciences 1180(1): 119- 124. https: doi.org 10.1111 j.1749-6632.2009.04947.x Fox NC, Black RS, Gilman S, LRossor MN, Griffith SG, Jenkins L, Koller M (2005) AN1792 (QS-21)-201 Study. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology (2005) 64(9): 1563- 1572. https: doi.org 10.1212 01.WNL.0000159743.08996.00 Schenk D (2002) Amyloid-u03b2 immunotherapy for Alzheimeru2019s disease: the end of the beginning. Nature Reviews 3: 824- 828. https: doi.org 10.1038 nrn938 ,